



NEWS RELEASE

Repligen to Host Investor & Analyst Event on October 16

2014-10-10

- Discussion of Biomanufacturing Trends and Technologies Will be Webcast -

WALTHAM, Mass., Oct. 10, 2014 (GLOBE NEWSWIRE) --Repligen Corporation (Nasdaq:RGEN) today announced that the Company will host an Investor & Analyst Event on October 16, 2014 in New York. The event, which will begin at 8:00 a.m. and conclude by 9:30 a.m. (EDT), will feature a presentation by Howard L. Levine, Ph.D., co-founder and President of BioProcess Technology Consultants. Dr. Levine is a recognized thought leader and published expert on the subject of biopharmaceuticals process development and manufacturing. Repligen speakers will include key members of the Company's management team: Walter C. Herlihy, Ph.D., President and CEO; Tony J. Hunt, COO; and Jon K. Snodgres, CFO. Dr. Levine will discuss factors that are driving significant changes in biomanufacturing, and Repligen management will discuss the Company's role in advancing bioprocessing technologies that increase facility efficiency and flexibility.

Attendance at this Investor & Analyst Event is limited to institutional investors and sell side analysts. To request an invitation and/or reserve a space, please contact Veronica Molina at LifeSci Advisors at 647-597-6987 or email vmolina@lifesciadvisors.com.

At the time of the event, a live webcast will be accessible from the **Investors section** of Repligen's website or through the following link: <http://lifesci.rampard.com/20141016>.

About Repligen Corporation

Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our

bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical component of Protein A media that is used to separate and purify monoclonal antibody therapeutics. Our ATF (Alternating Tangential Flow) System and our growth factor products are used to increase product yield during the fermentation stage of biologic drug manufacturing. In addition, we developed and market an innovative line of "ready-to-use" chromatography columns under our OPUS® brand (Open-Platform User-Specified) that we deliver pre-packed with our customers' choice of purification media. Repligen's corporate headquarters are in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA and Lund, Sweden.

This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like "believe," "expect," "may," "will," "should," "seek," or "could" and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.

CONTACT: Repligen Corporation
Sondra Newman
Director Investor Relations
(781) 419-1881
snewman@repligen.com

Source: Repligen Corporation